Astrana Health (ASTH) Cost of Revenue (2010 - 2026)

Astrana Health (ASTH) has 17 years of Cost of Revenue data on file, last reported at $859.4 million in Q1 2026.

• Quarterly Cost of Revenue rose 56.51% year-over-year to $859.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 58.97% YoY) and the FY2025 annual result came in at $2.8 billion, up 61.09% from the prior year.
• Cost of Revenue was little changed at $859.4 million in Q1 2026 per ASTH's latest filing, from $855.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $859.4 million in Q1 2026, with the low at $220.7 million in Q1 2022.
• Average Cost of Revenue over 5 years is $445.8 million, with a median of $330.4 million recorded in 2024.
• Year-over-year, Cost of Revenue grew 14.17% in 2024 and surged 111.95% in 2025.
• Astrana Health's Cost of Revenue stood at $253.1 million in 2022, then gained by 24.07% to $314.1 million in 2023, then surged by 95.74% to $614.7 million in 2024, then soared by 39.16% to $855.5 million in 2025, then increased by 0.45% to $859.4 million in 2026.
• Business Quant data shows ASTH's Cost of Revenue at $859.4 million in Q1 2026, $855.5 million in Q4 2025, and $858.9 million in Q3 2025.